With a bold strategic acquisition, this commercial-stage company has taken a transformative leap - broadening its revenue base with synergistic assets and positioning itself for sustained, long-term growth.
The company we are profiling today is CorMedix Inc. (CRMD), whose lead product is DefenCath, indicated for the prevention of catheter-related bloodstream infections in patients undergoing hemodialysis through a central venous catheter.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.